The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies’ pipelines as they tighten their focus on the projects with the most chance of a good return on investment.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,